公开(公告)号：US11866792B2

公开(公告)日：2024-01-09

申请号：US17940625

申请日：2022-09-08

申请人： CellMax Ltd.

发明人： Huangpin B. Hsieh ,  XiaoMing Wang ,  Jr-Ming Lai ,  Rui Mei ,  Hung-Jen Shao ,  Jen-Chia Wu

IPC分类号： G06K9/00 ,  C12Q1/6886 ,  G01N15/14 ,  G01N33/574 ,  G01N33/50 ,  G01N1/31 ,  G01N33/58 ,  C12Q1/6883 ,  G06T7/00

CPC分类号： C12Q1/6886 ,  G01N1/31 ,  G01N15/1475 ,  G01N33/5094 ,  G01N33/57484 ,  G01N33/582 ,  C12Q1/6883 ,  G01N15/1468 ,  G01N2015/1472 ,  G01N2333/4742 ,  G01N2333/70589 ,  G06T7/0012 ,  G06T2207/10056 ,  G06T2207/30096 ,  G06T2207/30101

摘要： A method for identifying candidate target cells within a biological fluid specimen includes a digital image of the biological fluid specimen with the digital image having a plurality of color channels, identifying first connected regions of pixels of a minimum first intensity in a first channel, identifying second connected regions of pixels of a minimum second intensity in a second channel, and determining first connected regions and second connected regions that spatially overlap. For a pair of a first connected region and a second connected region that spatially overlap, whether the second connected region overlaps the first connected region by a threshold amount is determined, and if the second connected region overlaps the first connected region by the threshold amount then the portion of the image corresponding to the overlap is continued to be treated as a candidate for classification.

公开(公告)号：US11859253B2

公开(公告)日：2024-01-02

申请号：US16740799

申请日：2020-01-13

申请人： CellMax Ltd.

发明人： Huangpin B. Hsieh ,  XiaoMing Wang ,  Jr-Ming Lai ,  Rui Mei ,  Hung-Jen Shao ,  Jen-Chia Wu

IPC分类号： G06K9/00 ,  C12Q1/6886 ,  G01N15/14 ,  G01N33/574 ,  G01N33/50 ,  G01N1/31 ,  G01N33/58 ,  C12Q1/6883 ,  G06T7/00

CPC分类号： C12Q1/6886 ,  G01N1/31 ,  G01N15/1475 ,  G01N33/5094 ,  G01N33/57484 ,  G01N33/582 ,  C12Q1/6883 ,  G01N15/1468 ,  G01N2015/1472 ,  G01N2333/4742 ,  G01N2333/70589 ,  G06T7/0012 ,  G06T2207/10056 ,  G06T2207/30096 ,  G06T2207/30101

摘要： A method for identifying and enumerating candidate target cells within a biological fluid specimen is described. The method includes obtaining a biological fluid specimen, preparing the biological fluid specimen by staining cell features in the biological fluid specimen, capturing a digital image having a plurality of color channels of the biological fluid specimen, and applying image analysis to the digital image. A computer program product for identifying candidate target cells within a biological fluid specimen is also described. The computer program comprises instructions to cause a processor to carry out the image analysis.

公开(公告)号：US20230384312A1

公开(公告)日：2023-11-30

申请号：US18249830

申请日：2021-10-22

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS ,  UNIVERSITE D'ANGERS ,  INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)

发明人： Maria del Carmen MARTINEZ ,  Pierre BIGOT ,  Luisa VERGORI

IPC分类号： G01N33/574

CPC分类号： G01N33/57438 ,  G01N33/57484 ,  G01N2333/988

摘要： A method of predicting the risk of recurrence in a subject undergoing treatment for, or having undergone treatment for, clear cell renal cell carcinoma (ccRCC), by comparing the level of extracellular vesicles, preferably microvesicles, expressing carbonic anhydrase 9 (CA9+ MVs) in a sample from the subject with a reference level. Also, a method of diagnosing ccRCC or identifying a risk of developing ccRCC, by comparing the level of CA9+ MVs in a sample from the subject with a reference level.

公开(公告)号：US11827704B2

公开(公告)日：2023-11-28

申请号：US16925980

申请日：2020-07-10

申请人： Novartis AG ,  DANA-FARBER CANCER INSTITUTE, INC. ,  PRESIDENT AND FELLOWS OF HARVARD COLLEGE

发明人： Gordon James Freeman ,  Arlene Helen Sharpe ,  Walter A. Blattler ,  Jennifer Marie Mataraza ,  Catherine Anne Sabatos-Peyton ,  Hwai Wen Chang ,  Gerhard Johann Frey

IPC分类号： G01N33/574 ,  C07K16/28 ,  G01N33/566 ,  G01N33/68 ,  A61K45/06 ,  C07K16/30

CPC分类号： C07K16/2818 ,  A61K45/06 ,  C07K16/2896 ,  C07K16/30 ,  G01N33/566 ,  G01N33/57484 ,  G01N33/6854 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N2333/70596 ,  Y02A50/30

摘要： Antibody molecules that specifically bind to PD-1 are disclosed. The anti-PD-1 antibody molecules can be used to treat, prevent and/or diagnose cancerous or infectious conditions and disorders.

公开(公告)号：US20230375527A1

公开(公告)日：2023-11-23

申请号：US18110341

申请日：2023-02-15

申请人： The Regents of the University of California

发明人： Stephanie Fraley ,  Hannah Carter ,  Daniel Ortiz Velez ,  Brian Tsui

IPC分类号： G01N33/50 ,  C12N5/09 ,  C12Q1/6886 ,  G01N33/574

CPC分类号： G01N33/5011 ,  C12N5/0693 ,  C12Q1/6886 ,  G01N33/5023 ,  G01N33/57484 ,  C12N2533/54 ,  C12N2533/90 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/52

摘要： Disclosed herein is a novel gene signature of metastatic cancer cells and a novel three-dimensional (3D) culture system for use in improved methods of predicting metastasis or prognosis in cancer. Accordingly, described herein are methods of determining a risk of metastasis, methods of predicting prognosis for cancer patients, methods of treating a cancer patient identified at high risk of metastasis, methods of treating a cancer patient identified as having poorer prognosis, methods for determining the migration capacity of a tumor, methods of screening a tumor for sensitivity to a drug, and kits for use in performing these methods.

公开(公告)号：US20230372460A1

公开(公告)日：2023-11-23

申请号：US18081178

申请日：2022-12-14

申请人： LURONG ZHANG

发明人： LURONG ZHANG

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/09 ,  C12N13/00 ,  G01N33/68 ,  G01N33/574

CPC分类号： A61K39/0011 ,  A61P35/00 ,  C12N5/0693 ,  C12N13/00 ,  G01N33/6854 ,  G01N33/57484 ,  C12N2521/00

摘要： The invention relates to induced neoantigen vaccines and a method of using same to treat cancer by enhancing a patient's anti-cancer immunity. The method involves application of an induction radiation to the patient to generate an “in situ vaccine” in vivo, subsequent removal of the tumor, subjecting its cells to a survival pressure for further production of neoantigens in vitro, and processing of the cells to obtain a self-tumor vaccine. The invention provides comprehensive mobilization of individualized anti-cancer active immunity via sequential combination of means of cancer treatments (e.g., radiotherapy, surgery, chemotherapy). Another aspect of the invention relates to an immunoassay protocol to monitor parameters indicative of the cellular and humoral anti-cancer immunity of a patient.

公开(公告)号：US20230340118A1

公开(公告)日：2023-10-26

申请号：US18315294

申请日：2023-05-10

申请人： DAIICHI SANKYO COMPANY, LIMITED

发明人： Keisuke FUKUCHI ,  Kayoko NANAI ,  Masato AMANO ,  Kozo YONEDA ,  Yusuke TOTOKI ,  Shoji YAMAMOTO

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K47/68 ,  A61K45/06 ,  G01N33/574 ,  A61K39/395 ,  A61K39/00

CPC分类号： C07K16/2803 ,  A61P35/00 ,  A61K47/6803 ,  A61K45/06 ,  A61K47/6849 ,  G01N33/57484 ,  A61K39/3955 ,  C07K2317/622 ,  C07K2317/21 ,  C07K2317/734 ,  C07K2317/732 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/24 ,  C07K2317/33

摘要： An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.

公开(公告)号：US11798653B2

公开(公告)日：2023-10-24

申请号：US16657375

申请日：2019-10-18

申请人： MEDIMMUNE, LLC

发明人： Li Yu ,  Harry Yang ,  Mohammed Dar ,  Lorin Roskos ,  Jean-Charles Soria ,  Charles Ferte ,  Wei Zhao ,  Aline Gendrin Brokmann ,  Jolyon Faria ,  Pralay Mukhopadhyay ,  Ikbel Achour

IPC分类号： G16B40/20 ,  G16B5/20 ,  G06N20/20 ,  G16H50/20 ,  G16H50/50 ,  G16H50/30 ,  G06N5/01 ,  G16H20/40 ,  A61K38/00 ,  C07K16/28 ,  G01N33/574

CPC分类号： G16B40/20 ,  G06N5/01 ,  G06N20/20 ,  G16B5/20 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  A61K38/00 ,  C07K16/2818 ,  G01N33/57484 ,  G16H20/40

摘要： Methods for determining treatments for cancer patients are disclosed.

公开(公告)号：US11795197B2

公开(公告)日：2023-10-24

申请号：US16616692

申请日：2018-06-07

申请人： Cedars-Sinai Medical Center

发明人： Yong Yue ,  Yi Zhang

IPC分类号： C07K7/06 ,  A61K45/06 ,  A61K49/00 ,  A61K49/14 ,  A61K51/08 ,  G01N33/574 ,  A61K38/00

CPC分类号： C07K7/06 ,  A61K45/06 ,  A61K49/0002 ,  A61K49/0056 ,  A61K49/14 ,  A61K51/088 ,  G01N33/57484 ,  A61K38/00

摘要： Described herein is a peptide, a multimodal peptide ligand imaging agent and methods for use in tumor targeting, tumor visualization, drug delivery and as an imaging ligand. The invention further provides for a theranostic peptide agent and methods for use in the treatment of cancer and/or inflammation in a subject.

公开(公告)号：US20230333112A1

公开(公告)日：2023-10-19

申请号：US18174246

申请日：2023-02-24

申请人： Marengo Therapeutics, Inc.

发明人： Andreas Loew ,  Madan Katragadda ,  Gurkan Guntas ,  Peter Marek ,  Sangeetha Palakurthi

IPC分类号： G01N33/574 ,  C07K16/28 ,  A61P35/00

CPC分类号： G01N33/57484 ,  C07K16/2809 ,  A61P35/00 ,  A61K2039/505

摘要： Antibody molecules that bind to TRBC1 or TRBC2 are disclosed. Additionally disclosed are methods of detecting TRBC1 or TRBC2, methods of evaluating a subject or a disorder, and kits using the aforesaid antibody molecules.